Skip to main content
. Author manuscript; available in PMC: 2019 Jan 9.
Published in final edited form as: Mucosal Immunol. 2018 Jul 9;11(5):1454–1465. doi: 10.1038/s41385-018-0051-2

Figure 4.

Figure 4

Prophylactic anti-Thy 1.2 reduces ILCs and ameliorates colitis in TRAG mice. IP injections of anti-Thy 1.2 (1 mg) were administered to TRAG mice from 4–6 weeks of age every three days. Anti-Thy1.2 treatment reduced colitis in TRAG mice as indicated by (a) colon length and gross morphology and (b,c) histology. TRAG mice treated with anti-Thy1.2 antibody prior to the development of colitis displayed reduced numbers of colonic mucosal (d) ILC, (e) neutrophils and (f) inflammatory myeloid cells, compared to control TRAG mice. (Mann-Whitney for (b); T test for other data) *p<0.05, p<0.005. Data represent 2 independent experiments, mean ± SEM (n = 8–10 mice/group).